Last Updated: 26 May 2026
Neurosoft Bioelectronics, a Swiss neurotechnology company, has spent years working on a deceptively simple idea: build a brain electrode soft enough to fold through a small incision and unfold inside the skull, reaching areas of the brain that rigid devices cannot. The company was spun out of EPFL in Geneva and is now running clinical trials in two countries, putting it further along the path to market than most of its peers.
Brain-computer interfaces, known as BCIs, create a direct link between the brain and an external device by reading electrical signals from brain tissue. In medicine, they are used to help people with epilepsy, paralysis, and other severe neurological conditions. The global BCI market is projected to grow from around $2.9 billion in 2025 to nearly $13.9 billion by 2035, according to Precedence Research, driven by rising rates of neurological disease and the growing use of AI to interpret neural data. Earlier this year, US-based Synchron announced a roadmap for a foundation model of human cognition to be trained on large-scale neural recordings, a sign that major investment in AI-powered brain interfaces is accelerating.
Neurosoft has raised $7.5 million in a seed round that closed oversubscribed, bringing its total funding to more than $20 million. Skybound Venture Capital led the round, with PL Capital, IAG Capital Partners, Connecticut Innovations, and others taking part.
Most brain interfaces face a structural limitation. The brain's surface is heavily folded, and conventional devices can only rest on top of it, leaving large sections of the cortex unreachable. Rigid or semi-rigid electrodes also tend to cause the brain to react over time, forming scar tissue that degrades signal quality and shortens device life.
Neurosoft builds its electrodes from soft, elastic materials. The device can be folded to fit through a small opening in the skull, then spread out once inside, covering far more of the cortex than a rigid device could reach. The company says its electrodes are up to 1,000 times more flexible than other flexible neural interfaces on the market and can cover up to 30 times more cortical surface area, all through a minimally invasive procedure.
The bigger the coverage, the richer the data. Neurosoft is using that data to train what it calls a cortical foundation model, an AI system built on its own neural recordings, in much the same way that large language models are built on text. The goal is to improve clinical outcomes for patients first, then eventually extend the model's usefulness to non-invasive brain interface devices.
"Neurosoft isn't just building a medical device; they are building the definitive interface between the human mind and the digital world. Their stretchable, sub-millimeter electrodes are a feat of engineering that finally allows us to interface seamlessly with the brain without damaging it. We are proud to lead this investment to accelerate their mission of treating devastating conditions like severe tinnitus and epilepsy, while simultaneously gathering the unprecedented neural data required to map and decode the human cortex at scale."
George Varvarelis, GP at Skybound Venture Capital
The new capital is directed at two goals: demonstrating minimally invasive deployment in human patients and reaching commercial launch in the United States. Neither goal starts from scratch. Neurosoft has already received FDA feedback through multiple pre-submission meetings and holds ISO 13485 certification, the international quality standard for medical device manufacturers. It runs a GMP-certified production line in Switzerland, meaning it manufactures under the conditions required for clinical and commercial supply.
The company has two active clinical trials running in parallel. One is at UTHealth Houston in the US; the other at UMC Utrecht in the Netherlands. One of those studies is the first of its kind to use a 64-channel soft, stretchable brain interface for epilepsy surgery guidance. Ten patients have been enrolled across both trials so far, providing the kind of real-world clinical data that regulators and future commercial partners look for.
Neurosoft also announced a partnership with Science Corp earlier this year, which the company says will help accelerate development of its BCI platform in addition to the new funding.
Founded at EPFL in Geneva, Neurosoft is headquartered in Switzerland with a US subsidiary in New York. The company has published its research in more than 25 peer-reviewed articles and holds over 25 patents covering its electrode platform. Its current clinical work focuses on epilepsy and severe tinnitus. Longer term, the company aims to develop a cortical foundation model that could improve outcomes for both implanted and non-invasive brain interfaces.
"Our soft electrode platform, paired with a streamlined regulatory pathway, gives us access to neural data at a quality and scale no other approach can safely match today. That data is the foundation for improved clinical outcomes, and a cortical foundation model that will help shape the next generation of brain interfaces. The investor support we've seen in this round validates that we're on the right path."
Nicolas Vachicouras, PhD, CEO and Co-Founder of Neurosoft Bioelectronics
Skybound Venture Capital, which focuses on early-stage deep tech, climate, and AI companies, led the seed investment. PL Capital, IAG Capital Partners, and Connecticut Innovations also participated, bringing together a mix of specialist and regional backers.
The round closed oversubscribed, meaning investor interest exceeded what Neurosoft was initially seeking. That outcome is uncommon at the seed stage for medical device companies, where long regulatory timelines and high development costs tend to limit early investor appetite. The clinical data Neurosoft has already generated, including results from patients across the US and Europe, appears to have been a material factor in attracting that level of interest.
